8 Results for "

glycated hemoglobin

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "glycated hemoglobin" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-12528
CAS No.: 1186426-66-3
Purity:  98.75%
Research Areas:  

Metabolic Disease

DBPR108 is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 15 nM. DBPR108 reduces glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose levels, increases serum active GLP-1 and insulin levels, and improves glucose tolerance. DBPR108 can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P11274A
Synonyms: Amycretin sodium; NN 9487 sodium
Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
Cat. No.: HY-14945
CAS No.: 442201-24-3
Purity:  99.81%
Synonyms: GSK189075
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
loading...
    loading...
Cat. No.: HY-P11274
CAS No.: 3005889-81-3
Synonyms: Amycretin; NN 9487
Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
Cat. No.: HY-114516
CAS No.: 10003-64-2
Purity:  99.79%
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Fructosylvaline (Fructose Valine) is a model fructosyl-amine (Amadori compound) for glycated hemoglobin. Fructosylvaline can be used as a nitrogen source to cultivate microbial strains .
loading...
    loading...
Cat. No.: HY-106181
CAS No.: 185428-18-6
Purity:  98.59%
Synonyms: R-106056
Target:  

PPAR

Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-13414
CAS No.: 329045-45-6
Synonyms: Remogliflozin A
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a Ki of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-109089S
Synonyms: 15(S)-HEPE-d5 ethyl ester; 15(S)-Hydoxy EPA-d5 ethyl ester; 15(S)-Hydoxy eicosapetaeoic acid-d5 ethyl ester
Epeleuton-d5 (15(S)-HEPE-d5 ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers .
loading...
    loading...